Severe bone marrow suppression following single-dose methotrexate treatment for ectopic pregnancy
| dc.contributor.author | Dündar, Betül | |
| dc.contributor.author | Dinçgez Çakmak, Burcu | |
| dc.contributor.author | Özgen, Gülten | |
| dc.contributor.author | Ketenci Gencer, Fatma | |
| dc.contributor.author | Aydın Boyama, Burcu | |
| dc.date.accessioned | 2022-04-13T09:30:14Z | |
| dc.date.available | 2022-04-13T09:30:14Z | |
| dc.date.issued | 2017 | |
| dc.department | İstanbul Medipol Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Kadın Hastalıkları ve Doğum Ana Bilim Dalı | |
| dc.description.abstract | Methotrexate is associated with multisystem side effects which depend on the dosage, route of administration and length of treatment. Bone marrow suppression is a very rare but one of the most mortal complications. A case of severe bone marrow suppression following single dose methotrexate for ectopic pregnancy was presented in this study. A 33-year-old woman, diagnosed as ectopic pregnancy, was given single-dose intramuscular methotrexate of 50 mg/m². On 10th day patient was admitted with lethargy, irritability, vomiting, hematemesis, diarrhea, oral mucositis and skin rash. Laboratory findings revealed severe bone marrow suppression. Supportive treatment together with antibacterial/ antifungal drugs and granulocyte colony stimulating factors were administered. On the 3rd day of treatment, mucositis and oral intake began to improve. After 1 week complete blood count was normal. Methotrexate may have mortal clinical consequences even with very low doses. Therefore, a careful patient history for patient selection and closer clinical follow-up are essential. | |
| dc.identifier.citation | Dündar, B., Dinçgez Çakmak, B., Özgen, G., Ketenci Gencer, F. ve Aydın Boyama, B. (2017). Severe bone marrow suppression following single-dose methotrexate treatment for ectopic pregnancy. The European Research Journal, 3(3), 285-289. https://doi.org/10.18621/eurj.304373 | |
| dc.identifier.doi | 10.18621/eurj.304373 | |
| dc.identifier.endpage | 289 | |
| dc.identifier.issue | 3 | |
| dc.identifier.startpage | 285 | |
| dc.identifier.trdizinid | TWprek1UZzNOdz09 | |
| dc.identifier.uri | https://doi.org/10.18621/eurj.304373 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12511/9326 | |
| dc.identifier.volume | 3 | |
| dc.indekslendigikaynak | TR-Dizin | |
| dc.institutionauthor | Aydın Boyama, Burcu | |
| dc.language.iso | en | |
| dc.publisher | Prusa Medikal Yayıncılık | |
| dc.relation.ispartof | The European Research Journal | en_US |
| dc.relation.publicationcategory | Makale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanı | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.subject | Bone Marrow Suppression | |
| dc.subject | Ectopic Pregnancy | |
| dc.subject | Methotrexate | |
| dc.subject | Side Effects | |
| dc.subject | Single-Dose Regimen | |
| dc.title | Severe bone marrow suppression following single-dose methotrexate treatment for ectopic pregnancy | |
| dc.type | Article |
